Fast track designation from FDA for development of eftilagimod alpha (efti), a soluble lag-3 protein, in first line recurrent/metastatic head & neck cancer

Fast track designation has been granted following promising results from Part C Phase II TACTI-002 trial evaluating efti in combination with pembrolizumab. The overall response rate reported was approximately 36% patients receiving this combination.

Source:

Biospace Inc.